BREAST CANCER RESISTANCE PROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 357

196. Huss, WJ, Gray, DR, Greenberg, NM, Mohler, JL, and Smith, GJ. 2005. Breast cancer
resistance protein-mediated efflux of androgen in putative benign and malignant prostate
stem cells. Cancer Res 65:6640-6650.
197. van der Heijden, J, de Jong, MC, Dijkmans, BA, Lems, WF, Oerlemans, R, Kathmann,
I, Schalkwijk, CG, Scheffer, GL, Scheper, RJ, and Jansen, G. 2004. Development of
sulfasalazine resistance in human T cells induces expression of the multidrug resistance
transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis
63:138-143.
198. van der Heijden, J, de Jong, MC, Dijkmans, BA, Lems, WF, Oerlemans, R, Kathmann,
I, Scheffer, GL, Scheper, RJ, Assaraf, YG, and Jansen, G. 2004. Acquired resistance
of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to
non-related DMARDs. Ann Rheum Dis 63:131-137.
199. Ji, Y, and Morris, ME. 2004. Effect of organic isothiocyanates on breast cancer resistance
protein (ABCG2)-mediated transport. Pharm Res 21:2261-2269.
200. Schrickx, J, Lektarau, Y, and Fink-Gremmels, J. 2005. Ochratoxin A secretion by ATP-
dependent membrane transporters in Caco-2 cells. Arch Toxicol 1-7.
201. Polli, JW, Baughman, TM, Humphreys, JE, Jordan, KH, Mote, AL, Webster, LO, Barn-
aby, RJ, Vitulli, G, Bertolotti, L, Read, KD, and Serabjit-Singh, CJ. 2004. The systemic
exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-
glycoprotein and breast cancer resistance protein efflux transporters. Drug Metab Dispos
32:722-726.
202. Kondo, C, Onuki, R, Kusuhara, H, Suzuki, H, Suzuki, M, Okudaira, N, Kojima, M,
Ishiwata, K, Jonker, JW, and Sugiyama, Y. 2005. Lack of improvement of oral absorption
of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast
cancer resistant protein (BCRP/ABCG2). Pharm Res 22:613-618.
203. Braun, AH, Stark, K, Dirsch, O, Hilger, RA, Seeber, S, and Vanhoefer, U. 2005. The
epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer
cells to irinotecan. Anticancer Drugs 16:1099-1108.
204. Zhang, S, Wang, X, Sagawa, K, and Morris, ME. 2005. Flavonoids chrysin and ben-
zoflavone, potent breast cancer resistance protein inhibitors, have no significant effect
on topotecan pharmacokinetics in rats or mdr1a/1b (

− / − ) mice. Drug Metab Dispos

33:341-348.
205. Yang, CH, Chen, YC, and Kuo, ML. 2003. Novobiocin sensitizes BCRP/MXR/ABCP
overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mi-
toxantrone. Anticancer Res 23:2519-2523.
206. Shiozawa, K, Oka, M, Soda, H, Yoshikawa, M, Ikegami, Y, Tsurutani, J, Nakatomi, K,
Nakamura, Y, Doi, S, Kitazaki, T, et al. 2004. Reversal of breast cancer resistance protein
(BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int
J Cancer 108:146-151.
207. Morita, H, Koyama, K, Sugimoto, Y, and Kobayashi, J. 2005. Antimitotic activity and
reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from
Bletilla striata . Bioorg Med Chem Lett 15:1051-1054.
208. Sargent, JM, Williamson, CJ, Maliepaard, M, Elgie, AW, Scheper, RJ, and Taylor,
CG. 2001. Breast cancer resistance protein expression and resistance to daunorubicin
in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115:257-
262.